Moreover, we demonstrated that Id is a critical driver of self-renewal, acting via Kif11 and Aurka. We found that the Id-expressing tumor cells were resistant to chemotherapy, which forms the first line of treatment in TNBC. Here, KIF11 is linked to neoplasm.